FDA announced additional draft and revised draft product-specific guidances for generic drug products. The Federal Register notice was published on May 22, 2026. The official tables list 22 new and 40 revised active-ingredient entries. Comments are requested by July 21, 2026. The recommendations address bioequivalence study design supporting abbreviated new drug applications (ANDAs).
What Do FDA’s 62 Listed Guidance Entries Mean?
FDA announced draft and revised draft product-specific guidances covering 62 listed active-ingredient entries. These guidances provide product-specific recommendations for bioequivalence study design supporting generic drug abbreviated new drug applications (ANDAs). The update helps developers identify relevant study considerations. However, the documents remain drafts and do not guarantee successful submissions, faster approvals, or immediate market entry for any proposed generic product.
Sides of FDA’s Generic Guidance Update
FDA’s update may support clearer generic development planning by giving bioequivalence specialists, CMC teams, and regulatory professionals current product-specific recommendations to assess ANDA strategies. Yet the guidances are still drafts. Teams may need to reassess study plans, formulation assumptions, and scientific evidence against evolving recommendations. Additional evaluation may be required, and following a draft guidance cannot guarantee approval, shorter review timelines, successful development, or market entry for proposed generic products.
Pharma Groups Tracking FDA’s Generic Shift
This update matters beyond the Federal Register. It connects bioequivalence study planning, CMC strategy, submission readiness, and career knowledge. Generic developers, CMC and BE specialists, regulatory professionals, students, and job seekers may need to follow the guidance landscape carefully now.
Generic Drug Developers: Reviewing Development Pathways
Generic drug developers may use FDA product-specific recommendations to evaluate development pathways, evidence expectations, and bioequivalence strategies needed to support robust abbreviated new drug applications for particular proposed drug products.
- Check draft PSGs relevant to planned generic products.
- Review bioequivalence assumptions before advancing development.
CMC and Bioequivalence Teams: Testing Study Readiness
CMC and bioequivalence specialists may examine formulation, testing, comparability, and study-design implications within relevant draft recommendations, aligning technical development choices with regulatory planning before an ANDA programme progresses toward submission.
- Assess product-specific bioequivalence study recommendations.
- Align scientific decisions with regulatory submission planning.
Regulatory Professionals and Students: Building ANDA Knowledge
Regulatory professionals, students, graduates, and pharma job seekers can strengthen practical career readiness by understanding product-specific guidances, bioequivalence evidence, ANDA pathways, and how FDA communicates draft development expectations for applicants.
- Learn how FDA guides generic drug development pathways.
- Build career-ready knowledge of ANDA and BE strategy.
62 Listed Entries That Could Shape ANDA Planning
FDA’s May 22, 2026 notice lists 22 new and 40 revised active-ingredient entries. This guidance update could support more informed bioequivalence and ANDA planning. However, results will depend on scientific evaluation, regulatory interpretation, development execution, stakeholder comments, and future FDA finalisation before any proposed generic medicine can move forward responsibly.
FDA’s new generic-guidance entries put ANDA knowledge in focus. Read Pharma Legislation Guide in 2026 and Build the regulatory insight needed for future generic-development decisions and career opportunities with confidence.